Table 4e. Characteristics of Antiviral Agents, Including Antibody Products

Last Updated: November 2, 2023

This table contains drugs and products that have shown antiviral activity against SARS-CoV-2, including small-molecule antiviral drugs, CCP, and IFNs.
RDV and RTV-boosted nirmatrelvir (Paxlovid) are approved by the FDA for the treatment of COVID-19.
MOV and CCP have received EUAs from the FDA for the treatment of COVID-19.
For drug-drug interaction information, please refer to product labels, EUA fact sheets, and Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications.
For the Panel’s recommendations on using the drugs listed in this table, refer to Antiviral Agents, Including Antibody Products; Therapeutic Management of Nonhospitalized Adults With COVID-19; Therapeutic Management of Hospitalized Adults With COVID-19; Therapeutic Management of Nonhospitalized Children With COVID-19; Therapeutic Management of Hospitalized Children With COVID-19; and Pregnancy, Lactation, and COVID-19 Therapeutics.

Table 4e. Characteristics of Antiviral Agents, Including Antibody Products
Table 4e. Characteristics of Antiviral Agents, Including Antibody Products

References

Ritonavir-boosed nirmatrelvir (Paxlovid) [package insert]. Food and Drug Administration. 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217188s000lbl.pdf.
Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization for Paxlovid. 2023. Available at: https://www.fda.gov/media/155050/download.
BC COVID Therapeutics Committee COVID Therapy Review and Advisory Working Group. Therapeutic brief: crushing nirmatrelvir/ritonavir (Paxlovid). 2022. Available at: http://www.bccdc.ca/Health-Professionals-Site/Documents/COVID-treatment/Crushing_Paxlovid.pdf.
Remdesivir (Veklury) [package insert]. Food and Drug Administration. 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214787s019lbl.pdf.
Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use Authorization for Lagevrio (molnupiravir) capsules. 2023. Available at: https://www.fda.gov/media/155054/download.
Food and Drug Administration. Fact sheet for health care providers: Emergency Use Authorization (EUA) of COVID-19 convalescent plasma for treatment of coronavirus disease 2019 (COVID-19). 2021. Available at: https://www.fda.gov/media/141478/download.